Abstract
Objective We aimed to investigate cardiotrophin-1 (CT-1) concentrations in
the serum of pregnant women with gestational diabetes mellitus (GDM).
Materials and methods This prospective non-interventional cohort study was
conducted with 160 pregnant women who applied to the Umraniye Training and
Research Hospital, Department of Obstetrics and Gynecology between October 2022
and May 2023. The GDM group was formed from 80 pregnant women who were diagnosed
with GDM according to the 75-g OGTT. The control group consisted of 80 healthy
pregnant women who were matched with the GDM group in terms of age and body mass
index and had a normal 75-g OGTT result. Two groups were compared in terms of
maternal serum CT-1 concentrations.
Results Both groups were similar in terms of demographic features and the
gestational week at blood sampling for CT-1 (p>0.05 for each). The mean
maternal serum CT-1 concentration was found to be 1420.9 pg/ml
in the GDM group, while it was determined as 1455 pg/ml in the
control group (p=0.738). When the GDM and control groups were divided
into two subgroups, normal weight and overweight according to the
participants’ BMI, serum CT-1 concentrations were found to be similar in
these four groups (p=0.084). When the GDM group was divided into two
groups of diet-only and the insulin-using group for blood glucose regulation and
compared with the control group, the three groups were also similar in terms of
serum CT-1 concentrations (p=0.189).
Conclusion CT-1 is an adipokine involved in the regulation of glucose
metabolism and has been suggested to be associated with the pathophysiology of
diabetes mellitus. In this study, serum CT-1 concentrations were found to be
similar in the group with GDM and the group with normal glucose tolerance.
Whether CT-1 contributes to the development of GDM is currently unclear and
requires further investigation.
Key words
Cardiotrophin-1 - diabetes mellitus - gestational diabetes mellitus - oral glucose
tolerance test
